Summary:

- The FDA announced several regulatory actions in September 2024, including the approval of a new treatment for a rare genetic disorder, the expansion of an existing drug's indication, and the issuance of a safety communication regarding a medical device.

- The approved treatment is a gene therapy for a rare genetic disorder that affects the nervous system, providing a new option for patients with this condition.

- The expanded drug indication allows for the use of an existing medication in the treatment of a related medical condition, broadening the drug's clinical applications.

- The safety communication informs healthcare providers and patients about potential risks associated with a specific medical device, emphasizing the FDA's commitment to monitoring product safety and ensuring public health.